



2017

Association for Molecular Pathology



NH₂

 HO_2



PAGE Mission Statement. Vision Statement. 2017 Board of Directors and Committee Chairs



Attendees at the 2017 AMP Annual Meeting.

International Education Initiatives

ROM THE PRESIDEN

Dear Colleagues,

Since 1995, the AMP has been the premier organization representing molecular diagnostics and molecular medicine. As our laboratories (with their cutting-edge technology) and expertise are increasingly involved in diagnosis, therapeutic decisions and monitoring of diseases, we are proud to stand at the forefront of modern medicine.

AMP brings together a diverse and dynamic community: we are molecular pathologists, clinical laboratorians, basic and translational scientists, test developers and manufacturers, technologists and trainees. Together, we advance the clinical practice, science, and excellence of our field through education, innovation, and advocacy to enable the highest quality health care.

Our community of experts collaborate tirelessly to generate clinical practice guidelines, advocate for patients, develop a comprehensive catalog of educational offerings, publish in *The Journal of Molecular Diagnostics*, our highly regarded research journal, and exchange key knowledge at our professional meetings.

The AMP Annual Meeting is where all aspects of new molecular testing are first discussed. In 2017, AMP held its largest annual meeting to date, and we also held our first ever AMP Global Congress on Molecular Pathology in Berlin, Germany. AMP is committed to being to a truly global society. We will host AMP Europe 2018 in Rotterdam, The Netherlands, and the 2019 Global Congress will be held in Hong Kong.

It has been my privilege to serve as your President and an honor to call AMP my professional home. I look forward to our community's continued successes.

Sincerely,

Federico A. Monzon AMP President



AMP President Federico A. Monzon, MD (left) and 2017 Program Committee Chair Daniel E. Sabath, MD, PhD, (right) congratulate Andrew P. Feinberg, MD, MPH on his 2017 Award for Excellence in Molecular Diagnostics.



AMP 2017 attendees network at AMP Central in the meeting's Exhibit Hall.


MISSION • VISION • PRINCIPLES

SAMP'S STRATEGIC PLAN IS DYNAMIC.

Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP's Mission, Vision, and Core Principles.

MISSION STATEMENT

The **ASSOCIATION FOR MOLECULAR PATHOLOGY** is a not-for-profit scientific society that advances the **CLINICAL PRACTICE**, **SCIENCE**, and **EXCELLENCE** of molecular and genomic laboratory medicine through **EDUCATION**, **INNOVATION**, and **ADVOCACY** to enable highest quality health care.






VISION STATEMENT

The **ASSOCIATION FOR MOLECULAR PATHOLOGY** seeks to be a global community of professionals that advances excellence in the clinical practice of molecular and genomic laboratory medicine through:

- Activities that foster INNOVATIVE and TRANSFORMATIVE PATIENT CARE and the translation of scientific discoveries into diagnostic tests and services
- EDUCATION PROGRAMS that promote clinical laboratory testing of high quality and utility
- ADVOCACY that supports the practice of molecular pathology to enhance patient care, addresses regulatory and payment issues, and facilitates the adoption of innovative laboratory testing and technologies
- Activities that facilitate knowledge transfer and COLLABORATION among professionals worldwide

CORE PRINCIPLES

- Quality Health Care Through EXCELLENCE in Clinical Molecular Testing
- Fostering the **GLOBAL COMMUNITY** of Molecular Pathology Professionals
- COLLABORATION to Advance Molecular Pathology
- ADVOCACY that Advances the Field and Practice of Molecular Pathology, Protects Patients, and Improves the Adoption of Innovative Technologies and Tests
- INNOVATION to Transform Patient Care



AMP 2017 attendees discuss research findings during a poster session in the meeting's Exhibit Hall.





PRESIDENT Federico A. Monzon, MD Castle Biosciences

PRESIDENT-ELECT AND STRATEGIC OPPORTUNITIES COMMITTEE CHAIR Kojo S. J. Elenitoba-Johnson, MD University of Pennsylvania, Perelman School of Medicine

PAST PRESIDENT AND NOMINATING COMMITTEE CHAIR Charles E. Hill, MD, PhD Emory University School of Medicine

SECRETARY-TREASURER AND FINANCE COMMITTEE CHAIR Andrea Ferreira-Gonzalez, PhD Virginia Commonwealth University/MCV Clinical Support Center

2017 AMP Board: (*l*-*r*, *f*-*b*) Ron M. Przygodzki, MD, Andrea Ferreira-Gonzalez, PhD, Antonia R. Sepulveda, MD, PhD, Roger D. Klein, MD, JD, Charles E. Hill, MD, PhD, David R. Hillyard, MD, Annette Kim, MD, PhD, Rami Mahfouz, MD, MPH, Federico A. Monzon, MD, Laura J. Tafe, MD, Daniel E. Sabath, MD, PhD, Alexis B. Carter, MD, Samuel K. Caughron, MD, Birgit Funke, PhD, Jane Gibson, PhD

CLINICAL PRACTICE COMMITTEE CHAIR Antonia R. Sepulveda, MD, PhD

BOARD

Columbia University Medical Center

ECONOMIC AFFAIRS COMMITTEE CHAIR Samuel K. Caughron, MD MAWD Pathology Group, PA

MEMBERSHIP AFFAIRS COMMITTEE CHAIR Pop M. Przycodzki, MD

Ron M. Przygodzki, MD Department of Veterans Affairs

PROFESSIONAL RELATIONS COMMITTEE CHAIR Roger D. Klein, MD, JD Klein & Klein Co. L.P.A

PROGRAM COMMITTEE CHAIR Daniel E. Sabath, MD, PhD University of Washington Medical Center

PUBLICATION & COMMUNICATION COMMITTEE CHAIR

Jane Gibson, PhD University of Central Florida College of Medicine

TRAINING & EDUCATION COMMITTEE CHAIR

Annette Kim, MD, PhD Brigham and Women's Hospital

GENETICS SUBDIVISION CHAIR

Birgit Funke, PhD Veritas Genetics

HEMATOPATHOLOGY SUBDIVISION CHAIR Todd W. Kelley, MD University of Utah INFECTIOUS DISEASES SUBDIVISION CHAIR David R. Hillyard, MD ARUP Laboratories, Inc.

INFORMATICS SUBDIVISION CHAIR Alexis B. Carter, MD Children's Healthcare of Atlanta

OF DIRECTORS

SOLID TUMORS SUBDIVISION CHAIR Laura J. Tafe, MD Dartmouth-Hitchcock Medical Center

INVITED GUEST INTERNATIONAL AFFAIRS COMMITTEE CHAIR Rami Mahfouz, MD, MPH American University of Beirut Medical Center

EXECUTIVE DIRECTOR Mary Steele Williams, MNA, MT(ASCP)SM, CAE

2017 AMP Executive Committee (I-r) Kojo S. J. Elenitoba-Johnson, MD, Charles E. Hill, MD, PhD, Federico A. Monzon, MD, Andrea Ferreira-Gonzalez, PhD, David R. Hillyard, MD







Andrew P. Feinberg, MD, MPH recipient of the 2017 Award for Excellence in Molecular Diagnostics addresses the annual meeting audience.

INTERNATIONAL AFFILIATES

The Hong Kong Society for Molecular Diagnostic Sciences The Korean Society for Laboratory Medicine The Molecular Pathology Association of India The German Society of Pathology Brazilian Society of Clinical Pathology and Laboratory Medicine The Italian Society of Pathology and Translational Medicine

ORGANIZATIONAL RELATIONSHIPS

AMP maintains **MEMBERSHIP** in the following organizations:

Association of Pathology Chairs (APC) Pathology Roundtable Cancer Leadership Council (CLC)

Federation of American Societies for Experimental Biology (FASEB) Global Alliance for Genomic Medicine

Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)

Intersociety Pathology Council (IPC) Personalized Medicine Coalition (PMC)

AMP maintains **RELATIONSHIPS** with the following groups:

Representative to ASCO CancerLinQ Steering Committee

Cooperating Society of the American Board of Pathology (ABP)

Steering Committee, NIST Genome in a Bottle Consortium

Associate Member of the Intersociety Council for Pathology Information Sponsor of the National Academy of Medicine Roundtable on Genomics and Precision Health

Representatives to FNIH Biomarkers Consortium Steering Committees Representative to the CAP Molecular Oncology Committee

Representative to the Pathology Coding Caucus

Liaisons to/from other professional societies on a project-specific basis





2017 President Federico A. Monzon, MD leads a "Lunch and Learn" session engaging patient advocates and explaining the importance of molecular testing.

In 2017, over **90 MEMBER VOLUNTEERS** worked on AMP efforts to foster excellence in

Test Directory, AMP

representation on outside

collaborative projects or

of three major reports:

clinical practice and patient care.

These efforts included the launch

committees, and the publication

of AMP's new and improved online

MOLECULAR MEDICINE

AMP ADVOCATES for excellence in molecular testing in clinical laboratories. We advance the field and practice of molecular pathology by representing the membership to the federal agencies and Congress to inform and influence public policy. AMP's clinical and scientific affairs initiatives aim to transform patient care through **INNOVATION**.

A D V O C A C Y

In 2017, AMP participated in numerous joint advocacy initiatives, hosted three "lunch and learns" with patient advocates, and led two payer summits with Medicare and private payer representatives. In addition, AMP submitted over **35 ADVOCACY COMMENT LETTERS** on issues such as:

- Medicare Coverage and Pricing for Molecular Pathology and Genomic Sequencing Procedures
- Protecting Access to Medicare Act (PAMA)
- Oversight of Laboratory Developed Procedures (LDPs)
- President Trump's Executive Order on Immigration
- Protecting the Genetic Information Nondiscrimination Act
- The Return of Individual-Specific Research Results Generated in Research Laboratories
- And Much More

INNOVATION & IMPROVED PATIENT CARE

Guidelines for Validation of Next-Generation Sequencing -Based Oncology Panels. A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists

J Mol Diagn. 2017 May; 19(3):341-365

Molecular Biomarkers for the Evaluation of Colorectal Cancer. Guideline from the American Society of Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology

J Mol Diagn. 2017 Mar;19(2):187-225

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists

J Mol Diagn. 2017 Jan;19(1):4-23



GLOBAL CONGRESS ON MOLECULAR PATHOLOGY

AMP GLOBAL 2017 Diagnostic Technologies and Clinical Applications Advancing Patient Care Through Molecular Medicine

MEMBERSHIP & MEETINGS

AMP ended the year with continued membership growth, rising from **2,370** in 2016 to **2,417** in 2017. Indicators suggest that growth will continue for the coming years. AMP members can be found in **47 COUNTRIES**.

Attendance continued to be strong at the **2017 ANNUAL MEETING**. We welcomed **2,200** attendees and approximately **1,530** exhibitors representing more than **180** companies. In addition, we welcomed nearly **500** attendees and **47** exhibiting companies at our **GLOBAL CONGRESS**.

		SCIENTIFIC
YEAR	LOCATION	ATTENDEES
2010	SAN JOSE, CA	1,266
2011	GAYLORD TEXAN, TX	1,343
2012	LONG BEACH, CA	1,674
2013	PHOENIX, AZ	1,720
2014	WASHINGTON, DC	1,944
2015	AUSTIN, TX	2,084
	CHARLOTTE, NC	
2017	SALT LAKE CITY, UT	2,201



2017 Global Congress on Molecular Pathology

2017 Global Congress on Molecular Pathology Organizing Committee members and International Affairs Committee members pose on stage at the opening ceremony.

AMP MEMBERS BY DEGREE:

PhD 834 (34.5%)	
MD 1022 (42.2%)	
Other 561 (23.3%)	

AMP MEMBERS WORK IN:

Academic Medical Centers (44%) Commercial Reference Labs (12%) Community Hospital Labs (8%) Government (3%) NGOs (6%) Industry (23%) Other (4%)



D ТНЕ W & N Α R 0 U Ν 0 R D 0 Ν E



AMP's educational initiatives continue to reach a global audience. In 2017, AMP hosted its inaugural **GLOBAL CONGRESS** on Molecular Pathology in Berlin, **GERMANY**. AMP invited speakers also presented at two AMP-affiliate society conferences in Bhubaneshwar, **INDIA** and Seoul, **KOREA**. In addition, AMP hosted its popular **INTERNATIONAL LUNCHEON** event at the AMP 2017 Annual Meeting.

As part of a strategic pivot towards online education, AMP launched AMP*ED*[™], a completely updated platform for hosting educational content, including webinars and recorded courses. To learn more, visit *educate.amp.org*















N



AMP's fiscal footing is solid, allowing it to dedicate significant resources to each of its strategic initiatives.

S

Sojet

4

Pr *FS

602

CCGGTQUETY

TTCCCC


GC

CGGG

Ν

C

STRATEGIC INITIATIVE REVENUE OVER EXPENSES	2017	2016	2015
Advocacy	\$ (437,181)	\$ (426,435)	\$ (425,166)
Communications & Outreach	\$ (193,658)	\$ (174,649)	\$ (206,633)
Education	\$ 1,932,749	\$ 2,299,693	\$ 2,800,434
Innovation & Improved Patient Care	\$ (288,701)	\$ (290,237)	\$ (280,556)
Membership & Management Services	\$ (208,213)	\$ (32,781)	\$ (502,766)
EXCESS REVENUE OVER EXPENSES	\$ 804,996	\$1,375,591	\$1,385,313



FHH



Association for Molecular Pathology

9650 Rockville Pike Bethesda, MD 20814







www.amp.org

